Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

BMC Urology

Table 1 Socio-demographic, tumor and treatment characteristics according to clinical TNM among 590 men with TGCT. Geneva 1970–2012

	Stage I		Stage II		Stage III		Unknown	Total		p-value for Chi2 heterogeneity test^a
	N	%	N	%	N	%	N	N	%	p-value for Chi2 heterogeneity test^a
Period
1970–1979	39	54.2	21	29.2	12	16.7	11	83	100	0.038
1980–1989	74	59.7	32	25.8	18	14.5	9	133	100
1990–1999	105	70	24	16	21	14	9	159	100
2000–2012	153	71.8	32	15	28	13.2	2	215	100
Age group
≤ 29	116	62	39	20.9	32	17.1	13	200	100	0.089
30–39	144	73.1	28	14.2	25	12.7	9	206	100
40–49	69	65.1	27	25.5	10	9.4	4	110	100
50+	42	60.9	15	21.7	12	17.4	5	74	100
Place of birth
Switzerland	289	68	75	17.6	61	14.4	25	450	100	0.342
Europe	61	59.8	26	25.5	15	14.7	6	108	100
Others	21	65.6	8	25	3	9.4	0	32	100
Social class
High	117	73.1	28	17.5	15	9.4	11	171	100	0.034
Medium	142	67.6	40	19	28	13.3	11	221	100
Low	81	57.4	31	22	29	20.6	6	147	100
Unknown	31	60.7	10	19.6	7	13.7	3	51	100
Morphology
Seminoma	245	74.5	60	18.2	24	7.3	11	340	100	<0.001
Non-seminoma	126	50.4	49	19.9	55	22	20	250	100	<0.001
Origin of diagnosis
Symptoms	311	65.3	92	19.3	73	15.3	16	492	100	0.736
Fortuitous	31	73.8	7	16.7	4	9.5	1	43	100
Check	8	66.7	3	25	1	8.3	0	12	100
Autopsy							1	1	100
Unknown	21	72.4	7	24.1	1	3.4	13	42	100
Radiotherapy
Seminoma
No	94	70.7	22	16.5	17	12.8	4	137	100	0.007
Yes	151	77.0	38	19.4	7	3.6	7	203	100	0.007
Non-seminoma
No	122	57.6	39	18.4	51	24.1	17	229	100	0.001
Yes	4	22.2	10	55.6	4	22.2	3	21	100	0.001
Chemotherapy
Seminoma
No	230	85.2	36	13.3	4	1.5	9	270	100	< 0.001
Yes	15	25.4	24	40.7	20	33.9	2	59	100	< 0.001
Non-seminoma
No	83	88.3	7	7.5	4	4.3	16	94	100	< 0.001
Yes	43	31.6	42	30.9	51	37.5	4	136	100	< 0.001

ISSN: 1471-2490